abstract |
(57) Summary The present invention identified a novel interferon gamma inducible factor-2 (IGIF-2) expressed in adenoid, brain, kidney, liver, lung, skin, synovium, and T lymphocytes, It provides an encoding polynucleotide (igif-2). The present invention also includes the antisense molecule in its scope. Further, the present invention relates to genetically engineered expression vectors and host cells for the production of purified IGIF-2; antibodies, antagonists and inhibitors; and pharmaceutical compositions and polypeptides, and the antibodies, antagonists, And a method for treating a disease based on an inhibitor. The invention is particularly useful as a therapeutic for immunocompromised patients, or as a positive control in a diagnostic assay to detect abnormal expression of IGIF-2 or altered leukocyte or lymphocyte activity. Is included in the scope. |